Matt Hadro reports for Catholic News Agency on the testing of chemical abortion drugs on women in Burkina Faso:
Pro-life advocates have condemned clinical testing of second trimester chemical abortions on women in a developing country in West Africa.
The tests are being conducted by Gynuity Health Projects, a U.S.-based research company, in Burkina Faso. The trials involve drugs which cause accelerated second trimester chemical abortions.
Since 2017, Gynuity has been conducting a clinical trial of second trimester abortions on pregnant women at 13 to 22 weeks gestation, “to examine the effectiveness and feasibility of a mifepristone-misoprostol medical abortion regimen.” The trial, currently in the “Recruiting” phase, is expected to be finished by the end of 2019.
Continue reading here.